229 related articles for article (PubMed ID: 23283300)
1. Management of uterine adenosarcomas with and without sarcomatous overgrowth.
Tanner EJ; Toussaint T; Leitao MM; Hensley ML; Soslow RA; Gardner GJ; Jewell EL
Gynecol Oncol; 2013 Apr; 129(1):140-4. PubMed ID: 23283300
[TBL] [Abstract][Full Text] [Related]
2. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
3. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Bernard B; Clarke BA; Malowany JI; McAlpine J; Lee CH; Atenafu EG; Ferguson S; Mackay H
Gynecol Oncol; 2013 Dec; 131(3):634-9. PubMed ID: 24135678
[TBL] [Abstract][Full Text] [Related]
4. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
5. Primary vaginal adenosarcoma with sarcomatous overgrowth.
Toyoshima M; Akahira J; Moriya T; Hayakawa S; Yaegashi N
Gynecol Oncol; 2004 Dec; 95(3):759-61. PubMed ID: 15582000
[TBL] [Abstract][Full Text] [Related]
6. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
7. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
8. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
9. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ; Conley AP
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1093-1100. PubMed ID: 30169984
[TBL] [Abstract][Full Text] [Related]
12. Uterine adenosarcomas: A dual-institution experience.
Özgü E; Narin MA; Yalçın HR; Taşçı T; Güngör T; Çavuşoğlu D; Meydanlı MM; Tulunay G
J Obstet Gynaecol; 2017 Jan; 37(1):93-96. PubMed ID: 27923317
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience.
Lee YJ; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
World J Surg Oncol; 2017 Apr; 15(1):87. PubMed ID: 28424089
[TBL] [Abstract][Full Text] [Related]
14. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of uterine cervical mullerian adenosarcoma: A clinicopathological study of six cases and review of the literature.
Togami S; Kawamura T; Fukuda M; Yanazume S; Kamio M; Kobayashi H
Taiwan J Obstet Gynecol; 2018 Aug; 57(4):479-482. PubMed ID: 30122564
[TBL] [Abstract][Full Text] [Related]
16. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
17. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.
Carroll A; Ramirez PT; Westin SN; Soliman PT; Munsell MF; Nick AM; Schmeler KM; Klopp AH; Fleming ND
Gynecol Oncol; 2014 Dec; 135(3):455-61. PubMed ID: 25449308
[TBL] [Abstract][Full Text] [Related]
18. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature.
Eichhorn JH; Young RH; Clement PB; Scully RE
Am J Surg Pathol; 2002 Oct; 26(10):1243-58. PubMed ID: 12360039
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
[TBL] [Abstract][Full Text] [Related]
20. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]